dc.creator | Alnaaimi M., Sulieman A., Alkhorayef M., Salah H., Alduaij M., Algaily M., Alomair O., Alashban Y., Almohammad H.I., Bradley D., Kappas C. | en |
dc.date.accessioned | 2023-01-31T07:31:00Z | |
dc.date.available | 2023-01-31T07:31:00Z | |
dc.date.issued | 2021 | |
dc.identifier | 10.1016/j.radphyschem.2021.109668 | |
dc.identifier.issn | 0969806X | |
dc.identifier.uri | http://hdl.handle.net/11615/70456 | |
dc.description.abstract | The objective of this study is to assess the patients' effective and organ dose during theranostic applications in Kuwait. In total, eighteen adults' patients were conducted nuclear medicine procedures with 177Lu Dotatate for theranostic purpose in Kuwait Cancer control center (KCCC), Kuwait. Medium energy collimator (MEC) (208 keV Scatter 26% better than 113 keV Scatter 60%) was utilized to obtain scans in definite time intervals ranged from one to 2 h (before voiding), 6:00, 24:00, 48:00, 72:00 h. Patients, tissue and organ radiation doses were computed utilizing OLINDA/EXM Software. The average radiation effective dose (in mSv/MBq) for bladder, liver, and both kidneys (left & right), were 0.36, 0.08, 0.61 & 0.60. The range of the effective dose was from 0.55 mSv to 7.7 mSv. The acquired scans using 177Lu were delivered diagnostic findings. The patients’ effective dose is lower compared to the previous studies. Variation is attributed to the departmental protocol and administered activity. The values of the mean organ dose were comparable and lower than previously published studies. Different organs have different level of doses, which may affected by the presence of the metastatic tumors in the entire organ. © 2021 Elsevier Ltd | en |
dc.language.iso | en | en |
dc.source | Radiation Physics and Chemistry | en |
dc.source.uri | https://www.scopus.com/inward/record.uri?eid=2-s2.0-85111288581&doi=10.1016%2fj.radphyschem.2021.109668&partnerID=40&md5=933e446be68a34ee959c4c1ddd0c0f49 | |
dc.subject | Diagnosis | en |
dc.subject | Dosimetry | en |
dc.subject | Radiation | en |
dc.subject | Radiology | en |
dc.subject | Adult patients | en |
dc.subject | Cancer control | en |
dc.subject | Control centre | en |
dc.subject | Effective dose | en |
dc.subject | Lu-177 | en |
dc.subject | Medium energy | en |
dc.subject | Organ dose | en |
dc.subject | Radiation risk | en |
dc.subject | Targeted radionuclide therapies | en |
dc.subject | Theranostics | en |
dc.subject | Nuclear medicine | en |
dc.subject | lutetium 177 | en |
dc.subject | oxodotreotide lutetium lu 177 | en |
dc.subject | prostate specific membrane antigen | en |
dc.subject | radioisotope | en |
dc.subject | adult | en |
dc.subject | Article | en |
dc.subject | bladder | en |
dc.subject | cancer radiotherapy | en |
dc.subject | clinical article | en |
dc.subject | digital imaging and communications in medicine | en |
dc.subject | dosimetry | en |
dc.subject | effective dose (radiation) | en |
dc.subject | fraction absorbed | en |
dc.subject | human | en |
dc.subject | kidney | en |
dc.subject | Kuwait | en |
dc.subject | liver | en |
dc.subject | male | en |
dc.subject | prostate cancer | en |
dc.subject | radiation dose | en |
dc.subject | radiation dose distribution | en |
dc.subject | radioactivity | en |
dc.subject | radioisotope therapy | en |
dc.subject | single photon emission computed tomography-computed tomography | en |
dc.subject | spleen | en |
dc.subject | Elsevier Ltd | en |
dc.title | Organs dosimetry in targeted radionuclide therapy | en |
dc.type | journalArticle | en |